IMS 2026 - Genetic risk factors and outcomes in ultra-high-risk multiple myeloma

In the exploratory genetic analysis of the OPTIMUM/MUKnine trial presented at IMS, what was the 4-year progression-free survival for ultra-high-risk patients with only two high-risk cytogenetic abnormalities and no high-risk gene expression profile or TP53 mutation?

100%
Around 60%
Below 40%, similar to patients with four or five adverse markers